Ayala Pharmaceuticals Presents Positive Interim Data from Phase 2 ACCURACY Trial of AL101 for the treatment of Recurrent/Metastatic Adenoid Cystic Carcinoma with Notch Activating Mutations at ESMO 2020
– Interim data showed meaningful clinical activity of AL101 4mg monotherapy with deep responses and 68% disease control rate
Read More
October 16, 2024 Exclusive Agreement Includes $18 Million in Milestone Payments to Orasis, Together with a Double-Digit Royalty on Sales...
October 29, 2024 MENLO PARK, Calif.–( BUSINESS WIRE )–Secret Double Octopus, the market leader in workforce passwordless authentication,...
ImmunoBrain Checkpoint Awarded $5 Million US NIA Grant for Phase 1b Alzheimer’s Disease Proof-of-Mechanism Study of Anti-PD-L1 IBC-Ab002...
Comments